MeSH term
Frequency | Condition_Probility | Diagnosis, Differential | 4 | 0.0 |
Humans | 415 | 0.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Models, Molecular | 6 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Temperature | 3 | 0.0 |
Amino Acid Motifs/genetics | 2 | 3.0 |
Circular Dichroism | 4 | 0.0 |
Complement 5/*metabolism | 19 | 82.0 |
Disulfides/chemistry | 2 | 2.0 |
Escherichia coli/genetics | 4 | 0.0 |
Oxidation-Reduction | 6 | 0.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 122 | 0.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Adult | 99 | 0.0 |
Chemotaxis/drug effects | 2 | 2.0 |
Comparative Study | 52 | 0.0 |
Complement 5a/*metabolism | 2 | 40.0 |
Complement Activation/*drug effects | 19 | 20.0 |
Deferoxamine/pharmacology | 2 | 4.0 |
Female | 125 | 0.0 |
Free Radical Scavengers/pharmacology | 2 | 3.0 |
Iron/pharmacology | 2 | 11.0 |
Male | 122 | 0.0 |
Middle Aged | 65 | 0.0 |
Research Support, Non-U.S. Gov't | 179 | 0.0 |
Zymosan/pharmacology | 7 | 7.0 |
Electrophoresis, Polyacrylamide Gel | 19 | 0.0 |
Epitopes | 2 | 0.0 |
Fertilization in Vitro | 2 | 1.0 |
Glycosylation | 4 | 0.0 |
Pregnancy | 10 | 0.0 |
Base Sequence | 24 | 0.0 |
English Abstract | 29 | 0.0 |
Molecular Sequence Data | 40 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Motor Cortex/*physiology | 2 | 10.0 |
Movement/*physiology | 3 | 7.0 |
Aged | 40 | 0.0 |
Antibody Specificity | 9 | 0.0 |
Immunohistochemistry | 13 | 0.0 |
Adolescent | 39 | 0.0 |
Child | 41 | 0.0 |
Complement/analysis | 13 | 9.0 |
Pedigree | 16 | 0.0 |
Recurrence | 5 | 0.0 |
Complement/*deficiency | 10 | 21.0 |
Complement Hemolytic Activity Assay | 5 | 10.0 |
Mass Screening | 2 | 1.0 |
Animals | 125 | 0.0 |
Cells, Cultured | 27 | 0.0 |
Complement Membrane Attack Complex/analysis | 2 | 12.0 |
Graft Rejection/*immunology | 2 | 2.0 |
*Models, Immunological | 2 | 4.0 |
Perfusion | 2 | 0.0 |
Swine | 9 | 0.0 |
Transplantation, Heterologous/*immunology | 2 | 3.0 |
Protein Binding | 10 | 0.0 |
Virus Replication | 3 | 0.0 |
Complement 4/physiology | 2 | 40.0 |
Antibodies, Monoclonal/immunology | 8 | 0.0 |
Conserved Sequence | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Epitopes/immunology | 2 | 0.0 |
HIV Envelope Protein gp120/immunology | 2 | 2.0 |
HIV Envelope Protein gp41/immunology | 2 | 9.0 |
HIV-1/*immunology | 5 | 1.0 |
Species Specificity | 9 | 0.0 |
Binding Sites | 18 | 0.0 |
Complement 3b/*metabolism | 3 | 3.0 |
Complement 5/metabolism | 21 | 48.0 |
Complement Factor B/metabolism | 5 | 12.0 |
Complement Factor H/metabolism | 2 | 15.0 |
Complement Pathway, Alternative | 9 | 7.0 |
In Vitro | 27 | 0.0 |
Ligands | 2 | 0.0 |
Surface Properties | 2 | 1.0 |
Complement 3/metabolism | 26 | 10.0 |
Complement 3 Convertase/*chemistry/*metabolism | 2 | 100.0 |
Kinetics | 24 | 0.0 |
Models, Biological | 6 | 0.0 |
Amino Acid Sequence | 35 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Blotting, Southern | 5 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Complement 3/genetics | 3 | 8.0 |
Complement 4/genetics | 3 | 4.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Complement 2/immunology | 2 | 18.0 |
Complement 3/immunology | 2 | 2.0 |
Complement Factor B/immunology | 2 | 22.0 |
Escherichia coli/immunology | 2 | 2.0 |
Leukocytes/immunology | 2 | 1.0 |
Cell Division/drug effects | 2 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 25 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Complement 5/*genetics | 2 | 100.0 |
Japan | 5 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
HIV Envelope Protein gp120/*chemistry/genetics/metabolism | 2 | 66.0 |
Protein Conformation | 12 | 0.0 |
Cluster Analysis | 2 | 1.0 |
Gene Expression | 7 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Complement Factor B/genetics | 3 | 4.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Reference Values | 9 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Sheep | 13 | 2.0 |
Cell Line | 14 | 0.0 |
Complement/*genetics | 3 | 5.0 |
Centrifugation, Density Gradient | 4 | 1.0 |
Immunoblotting | 4 | 0.0 |
Liver/enzymology | 2 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Binding Sites, Antibody | 4 | 1.0 |
Enzyme-Linked Immunosorbent Assay | 17 | 0.0 |
HIV Envelope Protein gp120/*immunology | 2 | 1.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Mice | 42 | 0.0 |
Child, Preschool | 12 | 0.0 |
Infant | 5 | 0.0 |
DNA Primers | 3 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
Protein Structure, Secondary | 5 | 0.0 |
Spectrophotometry, Ultraviolet | 2 | 1.0 |
T-Lymphocytes/*immunology | 3 | 0.0 |
Hemolysis | 29 | 9.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Rats | 12 | 0.0 |
Complement 3 Convertase/metabolism | 2 | 5.0 |
Complement 4/genetics/metabolism | 2 | 66.0 |
Complement Activation | 27 | 9.0 |
Hemolysis/immunology | 2 | 13.0 |
Trypsin/metabolism | 3 | 2.0 |
Phylogeny | 5 | 0.0 |
Disease Progression | 3 | 0.0 |
Carcinoma, Hepatocellular/*metabolism | 2 | 1.0 |
Liver/*metabolism | 2 | 0.0 |
Aged, 80 and over | 9 | 0.0 |
Alzheimer Disease/*metabolism | 4 | 1.0 |
Complement/genetics/*metabolism | 2 | 50.0 |
Complement Activation/*physiology | 2 | 8.0 |
Complement 5/deficiency/genetics | 2 | 100.0 |
Gene Frequency | 4 | 0.0 |
*Complement Activation | 45 | 11.0 |
Complement Activation/*immunology | 2 | 3.0 |
Prospective Studies | 7 | 0.0 |
Risk Factors | 2 | 0.0 |
Cross Reactions | 3 | 0.0 |
Radioimmunoassay | 6 | 0.0 |
Cellulose/*analogs & derivatives | 2 | 16.0 |
*Membranes, Artificial | 3 | 3.0 |
Receptors, Cell Surface/*analysis/immunology | 2 | 28.0 |
*Renal Dialysis | 2 | 0.0 |
Complement/*immunology | 6 | 4.0 |
*Graft Rejection | 4 | 4.0 |
Kidney/*immunology | 2 | 14.0 |
Renal Dialysis | 3 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Complement/*analysis | 39 | 22.0 |
Fetal Blood/*chemistry | 2 | 3.0 |
*Anesthesia | 2 | 13.0 |
Time Factors | 19 | 0.0 |
Blotting, Western | 8 | 0.0 |
Antibody Affinity | 2 | 1.0 |
Binding, Competitive | 9 | 0.0 |
Protein Denaturation | 2 | 0.0 |
Thermodynamics | 4 | 1.0 |
Antibodies/immunology | 2 | 0.0 |
Complement Activation/physiology | 2 | 10.0 |
Complement Membrane Attack Complex/*metabolism | 2 | 9.0 |
Neurons/*metabolism | 3 | 1.0 |
Rats, Wistar | 2 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Complement Pathway, Classical/*physiology | 2 | 18.0 |
Tissue Distribution | 3 | 0.0 |
Complement/*metabolism | 26 | 15.0 |
Magnesium/pharmacology | 3 | 2.0 |
Plasmids | 4 | 0.0 |
Recombination, Genetic | 3 | 0.0 |
Spleen/microbiology | 2 | 20.0 |
Mice, Inbred C3H | 3 | 0.0 |
*Cytotoxicity, Immunologic | 3 | 0.0 |
Aorta | 2 | 1.0 |
Binding, Competitive/immunology | 2 | 2.0 |
Chickens | 2 | 0.0 |
Complement 5/*immunology | 6 | 60.0 |
Complement Inactivators/*pharmacology | 3 | 11.0 |
Erythrocytes/immunology | 5 | 2.0 |
Biopsy | 4 | 0.0 |
Complement 3/analysis | 26 | 8.0 |
Properdin/analysis | 7 | 38.0 |
Action Potentials/physiology | 2 | 4.0 |
Retrospective Studies | 4 | 0.0 |
Family Health | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Neutrophils/*metabolism | 3 | 1.0 |
Peptide Mapping | 2 | 0.0 |
Complement Activation/immunology | 2 | 6.0 |
Disease Models, Animal | 3 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
*Plant Proteins | 2 | 3.0 |
Complement Membrane Attack Complex/metabolism | 2 | 5.0 |
Peptide Fragments | 2 | 2.0 |
Structure-Activity Relationship | 11 | 0.0 |
Blood Proteins/*analysis | 3 | 2.0 |
Gestational Age | 2 | 0.0 |
Infant, Newborn | 3 | 0.0 |
Collagen/*chemistry | 2 | 20.0 |
Solutions | 3 | 1.0 |
Trypsin Inhibitors/*chemistry | 2 | 66.0 |
Guinea Pigs | 25 | 3.0 |
Mutation | 5 | 0.0 |
Neutrophils/*immunology | 3 | 1.0 |
*Plasmids | 2 | 4.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Acute Disease | 12 | 0.0 |
Complement 5/*physiology | 2 | 33.0 |
Immunoglobulin G/immunology | 4 | 1.0 |
Immunoglobulin M/immunology | 3 | 2.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Complement Inactivators/pharmacology | 3 | 25.0 |
Dogs | 4 | 0.0 |
Macaca fascicularis | 2 | 0.0 |
Papio | 3 | 1.0 |
Rabbits | 23 | 0.0 |
Chemical Fractionation | 2 | 2.0 |
Chromatography, Gel | 5 | 0.0 |
Complement Pathway, Alternative/*drug effects | 4 | 18.0 |
Molecular Weight | 12 | 0.0 |
*Hemolysis | 11 | 12.0 |
Leukocytes/*physiology | 2 | 3.0 |
Complement 5/*deficiency | 10 | 100.0 |
Complement 5/analysis | 25 | 56.0 |
Complement Factor B/analysis | 7 | 16.0 |
Fluorescent Antibody Technique | 23 | 0.0 |
Immunoglobulin G/analysis | 5 | 1.0 |
Microscopy, Electron | 6 | 0.0 |
Alleles | 5 | 0.0 |
Complement 5/*deficiency/genetics | 6 | 100.0 |
Exons | 3 | 0.0 |
Mutation/*genetics | 3 | 0.0 |
Drug Design | 2 | 0.0 |
Hemolysis/drug effects | 5 | 8.0 |
Complement/deficiency | 3 | 30.0 |
Complement 5/immunology | 6 | 35.0 |
Blood Vessels/immunology | 4 | 66.0 |
Kidney Diseases/immunology/*pathology | 2 | 50.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Blood Bactericidal Activity | 4 | 4.0 |
Substrate Specificity | 2 | 0.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
*Evolution | 2 | 1.0 |
Flow Cytometry | 3 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Regression Analysis | 4 | 0.0 |
Complement 3/*biosynthesis | 4 | 9.0 |
Complement 5/*biosynthesis | 3 | 75.0 |
Fibroblasts/metabolism | 4 | 0.0 |
*Peptides | 2 | 3.0 |
Transfection | 2 | 0.0 |
Antibodies, Monoclonal | 6 | 0.0 |
*Complement Pathway, Classical | 6 | 6.0 |
Dose-Response Relationship, Immunologic | 9 | 1.0 |
Chromatography, Ion Exchange | 4 | 1.0 |
Complement/isolation & purification | 2 | 50.0 |
Complement 3/*isolation & purification | 2 | 18.0 |
Complement 5/*isolation & purification | 4 | 80.0 |
Complement 3 Nephritic Factor/*analysis | 3 | 37.0 |
Complement/metabolism | 8 | 8.0 |
Cycloheximide/pharmacology | 4 | 0.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Fetus | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
Chromatography, Affinity | 3 | 0.0 |
Complement/*physiology | 3 | 3.0 |
Heat | 5 | 0.0 |
Neutrophils/drug effects/*metabolism | 2 | 3.0 |
Lung/pathology | 3 | 3.0 |
Mice, Inbred Strains | 2 | 0.0 |
Neutrophils/physiology | 6 | 5.0 |
Antibodies, Protozoan/*blood | 2 | 16.0 |
Plasmodium falciparum/*immunology | 2 | 4.0 |
Immunoglobulins/analysis | 10 | 4.0 |
Epithelial Cells | 2 | 0.0 |
Epithelium/metabolism | 2 | 0.0 |
Interferon-gamma, Recombinant/pharmacology | 2 | 1.0 |
Pulmonary Alveoli/*metabolism | 3 | 21.0 |
Properdin/metabolism | 4 | 26.0 |
Complement/*biosynthesis | 13 | 36.0 |
Complement 3/biosynthesis | 5 | 18.0 |
Complement 5/biosynthesis | 6 | 60.0 |
Complement 8/biosynthesis | 3 | 100.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Anaphylatoxins/*analysis | 2 | 66.0 |
Autoradiography | 2 | 0.0 |
*Blood Bactericidal Activity | 4 | 8.0 |
Complement 9/metabolism | 4 | 12.0 |
Cosmids | 2 | 0.0 |
*Genes, Bacterial | 2 | 2.0 |
Virulence | 3 | 1.0 |
Antigen-Antibody Complex/analysis | 3 | 2.0 |
Complement 2/analysis | 5 | 17.0 |
Complement 4/analysis | 18 | 8.0 |
Lupus Erythematosus, Systemic/*immunology | 3 | 2.0 |
Lupus Nephritis/immunology | 2 | 40.0 |
Chemotaxis, Leukocyte | 6 | 3.0 |
Neutrophils/immunology | 3 | 1.0 |
Blood Proteins/*metabolism | 4 | 2.0 |
Chromatography, High Pressure Liquid | 3 | 0.0 |
Serine Endopeptidases/*metabolism | 2 | 2.0 |
Evolution | 2 | 0.0 |
Complement 3/*analysis | 6 | 6.0 |
Complement 5/*analysis | 8 | 88.0 |
Glomerulonephritis, Membranoproliferative/*blood/etiology | 2 | 100.0 |
Meningitis, Meningococcal/*blood/*complications | 2 | 100.0 |
Blood | 2 | 1.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Macaca mulatta | 2 | 0.0 |
Complement 1/metabolism | 5 | 13.0 |
Gene Library | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Predictive Value of Tests | 4 | 0.0 |
Risk | 3 | 0.0 |
Haploidy | 3 | 2.0 |
Complement Membrane Attack Complex | 14 | 17.0 |
Sensitivity and Specificity | 3 | 0.0 |
Antibodies, Monoclonal/*immunology | 3 | 0.0 |
Complement 6/metabolism | 6 | 60.0 |
Complement 7/metabolism | 3 | 30.0 |
Complement 4/metabolism | 8 | 8.0 |
Basement Membrane/immunology | 5 | 9.0 |
Vitronectin | 2 | 5.0 |
Complement Pathway, Alternative/immunology | 2 | 15.0 |
Immunodiffusion | 10 | 3.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Trypsin | 5 | 3.0 |
Edetic Acid/pharmacology | 6 | 3.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Complement 3b Inactivators/metabolism | 5 | 20.0 |
Complement 5a/biosynthesis | 2 | 100.0 |
Complement Factor H | 8 | 10.0 |
*Complement Pathway, Alternative | 17 | 15.0 |
Polyethylene Glycols/pharmacology | 2 | 4.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Interferons/*pharmacology | 2 | 2.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Sepharose | 3 | 5.0 |
Complement 6/biosynthesis | 3 | 75.0 |
Complement 9/biosynthesis | 2 | 100.0 |
Microspheres | 2 | 1.0 |
Neutrophils | 3 | 4.0 |
Serum Albumin/analysis | 2 | 1.0 |
Streptococcal Infections/*complications | 2 | 15.0 |
Macrophages/*immunology | 4 | 1.0 |
Phagocytosis | 3 | 0.0 |
HLA Antigens/analysis | 2 | 0.0 |
Erythrocytes/*immunology | 3 | 1.0 |
Escherichia coli/*immunology | 2 | 5.0 |
DNA/genetics | 3 | 0.0 |
Glomerulonephritis, IGA/immunology | 2 | 66.0 |
Glomerulonephritis, Membranoproliferative/immunology | 2 | 33.0 |
Glomerulonephritis, Membranous/immunology | 2 | 100.0 |
Kidney Glomerulus/immunology | 2 | 6.0 |
Complement 5/biosynthesis/*metabolism | 2 | 100.0 |
Hydroxides/*pharmacology | 2 | 100.0 |
Hydroxyl Radical | 2 | 6.0 |
Cattle | 4 | 0.0 |
Hamsters | 4 | 0.0 |
Chronic Disease | 9 | 0.0 |
Urticaria/*immunology | 2 | 33.0 |
Complement Activating Enzymes/*antagonists & inhibitors | 3 | 50.0 |
Complement Pathway, Alternative/drug effects | 6 | 28.0 |
Interferon Type I/pharmacology | 2 | 4.0 |
Immunologic Deficiency Syndromes/*immunology | 2 | 5.0 |
Complement 3/physiology | 2 | 11.0 |
Blood Proteins/analysis | 6 | 3.0 |
Immunoglobulin Allotypes/*genetics | 3 | 13.0 |
Phenotype | 5 | 0.0 |
Peptide Fragments/isolation & purification | 2 | 3.0 |
Motor Activity/physiology | 2 | 2.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Macrophages/*metabolism | 2 | 0.0 |
Free Radicals | 2 | 1.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Immunity, Cellular | 2 | 0.0 |
Lipopolysaccharides/immunology | 2 | 1.0 |
Osmolar Concentration | 2 | 0.0 |
Hemolytic Plaque Technique | 4 | 6.0 |
Homozygote | 2 | 0.0 |
Complement 3 Convertase/*metabolism | 3 | 17.0 |
Complement 3b/metabolism | 6 | 5.0 |
Complement Activating Enzymes/*metabolism | 5 | 16.0 |
Complement 4/deficiency | 6 | 25.0 |
Complement 1 Inactivators/analysis | 2 | 22.0 |
Fibrinolysis | 2 | 1.0 |
Complement 5a | 8 | 25.0 |
*Immunization, Passive | 2 | 3.0 |
Immunoglobulins, Fab/*immunology | 2 | 7.0 |
Complement 3/deficiency/metabolism | 2 | 66.0 |
Glomerulonephritis, Membranoproliferative/*blood/immunology | 2 | 100.0 |
Complement 1q | 10 | 9.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Complement 5a, des-Arginine | 2 | 28.0 |
Antigen-Antibody Complex/immunology | 2 | 3.0 |
Complement/immunology | 4 | 4.0 |
Complement 4/immunology | 2 | 5.0 |
Complement Pathway, Classical | 7 | 5.0 |
Hemolysis/*drug effects | 2 | 5.0 |
Glomerulonephritis/*immunology | 6 | 15.0 |
Arthritis, Rheumatoid/*immunology | 5 | 2.0 |
Blood Donors | 2 | 0.0 |
Complement 6/deficiency | 4 | 66.0 |
Complement 7/deficiency | 2 | 66.0 |
Complement 8/deficiency | 2 | 50.0 |
Complement 3a | 4 | 16.0 |
Complement 3/*metabolism | 4 | 2.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Zymosan | 2 | 9.0 |
Complement 2/biosynthesis | 7 | 43.0 |
Complement 4/biosynthesis | 3 | 18.0 |
Complement Factor B/biosynthesis | 4 | 23.0 |
Detergents/pharmacology | 2 | 1.0 |
Albumins/analysis | 2 | 5.0 |
Complement 3d | 3 | 4.0 |
Lymphocyte Activation | 4 | 0.0 |
Receptors, Complement 3b | 3 | 0.0 |
Anaphylatoxins/*biosynthesis | 2 | 66.0 |
Complement 2/metabolism | 4 | 14.0 |
*Peptide Biosynthesis | 3 | 10.0 |
Complement 1/analysis | 12 | 24.0 |
Complement Activating Enzymes/analysis | 4 | 13.0 |
Chemistry | 2 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Antibodies | 2 | 0.0 |
*Complement 5 | 6 | 66.0 |
Irrigation | 2 | 3.0 |
Mesocricetus | 3 | 1.0 |
Biological Transport | 2 | 0.0 |
Electron Spin Resonance Spectroscopy | 3 | 1.0 |
Phospholipids/*blood | 2 | 6.0 |
Immunoglobulins/*analysis | 3 | 3.0 |
Leukocyte Count | 3 | 0.0 |
Complement 2/*deficiency | 3 | 5.0 |
Autoantibodies/analysis | 2 | 1.0 |
Immunologic Techniques | 3 | 0.0 |
Precipitation | 2 | 1.0 |
Immunoelectrophoresis | 15 | 6.0 |
Complement 9/immunology | 2 | 11.0 |
Complement 5/*biosynthesis/immunology | 2 | 100.0 |
Complement 3 Convertase | 6 | 66.0 |
Complement Activating Enzymes/biosynthesis | 2 | 33.0 |
*Cloning, Molecular | 2 | 0.0 |
Complement 5/*antagonists & inhibitors | 2 | 100.0 |
Complement Pathway, Classical/drug effects | 3 | 13.0 |
*Antibody Formation | 2 | 2.0 |
Erythrocytes/physiology | 2 | 5.0 |
Major Histocompatibility Complex | 3 | 1.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Complement 2/genetics | 2 | 4.0 |
Complement 5/genetics | 2 | 50.0 |
Complement Activating Enzymes/genetics | 2 | 100.0 |
*Complement Inactivators | 5 | 6.0 |
Cell Membrane/immunology | 2 | 0.0 |
Macrophages/immunology | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Treatment Outcome | 2 | 0.0 |
Neutrophils/metabolism | 2 | 1.0 |
Complement 1s | 2 | 9.0 |
Complement 2/deficiency | 4 | 17.0 |
Complement 3/deficiency | 3 | 17.0 |
Complement 5/deficiency | 3 | 30.0 |
Phagocytes/immunology | 2 | 8.0 |
Antibodies, Bacterial/physiology | 2 | 28.0 |
Cold | 3 | 2.0 |
Complement Fixation Tests | 3 | 3.0 |
Complement Inactivators/*blood | 2 | 28.0 |
Rosette Formation | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Complement 6/*metabolism | 2 | 66.0 |
Complement Activating Enzymes/*immunology | 2 | 22.0 |
Complement Activation/drug effects | 3 | 16.0 |
Azlocillin | 2 | 100.0 |
Complement 3 | 5 | 12.0 |
Complement 4 | 3 | 16.0 |
Methicillin/*pharmacology | 2 | 40.0 |
Molecular Conformation | 2 | 0.0 |
Oxacillin/*pharmacology | 2 | 50.0 |
Penicillin G/*pharmacology | 2 | 100.0 |
Penicillins/*pharmacology | 2 | 13.0 |
Bronchoalveolar Lavage Fluid/*enzymology | 2 | 50.0 |
Chemotactic Factors/metabolism | 2 | 13.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Pneumonia/*etiology | 2 | 28.0 |
*Pulmonary Alveoli | 2 | 66.0 |
Antigen-Antibody Complex/*analysis | 5 | 3.0 |
Peptide Hydrolases/*pharmacology | 2 | 40.0 |
Antigen-Antibody Complex | 5 | 2.0 |
Complement 3 Convertase/biosynthesis | 2 | 22.0 |
Neutrophils/drug effects/*immunology | 2 | 6.0 |
Complement 5/analysis/*metabolism | 2 | 100.0 |
Macromolecular Substances | 3 | 0.0 |
Paraproteinemias/*immunology | 2 | 10.0 |
Ultracentrifugation | 2 | 1.0 |
Lysosomes/enzymology | 2 | 3.0 |
Trypsin/pharmacology | 2 | 1.0 |
Complement 3 Convertase/analysis | 2 | 50.0 |
Complement 9/analysis | 8 | 30.0 |
Neoplasms/*immunology | 2 | 1.0 |
Binding Sites/genetics | 2 | 0.0 |
Immune Sera | 5 | 1.0 |
Antibodies/analysis | 2 | 1.0 |
Skin/pathology | 2 | 0.0 |
Immunoglobulin M/analysis | 3 | 1.0 |
Complement Inactivators/metabolism | 2 | 10.0 |
Antigens | 2 | 2.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Histamine/*pharmacology | 3 | 8.0 |
Histamine H2 Antagonists/pharmacology | 2 | 16.0 |
Complement 1 Inactivators/*deficiency/genetics | 2 | 100.0 |
Culture Techniques | 2 | 0.0 |
Blood Proteins/biosynthesis | 2 | 9.0 |
Immunoglobulin A/analysis | 3 | 1.0 |
Prognosis | 3 | 0.0 |
Transferrin/analysis | 2 | 2.0 |
Postpartum Period | 2 | 2.0 |
Pre-Eclampsia/*immunology | 2 | 14.0 |
*Pregnancy | 2 | 1.0 |
Antibody Formation | 3 | 0.0 |
Hemagglutination Tests | 2 | 2.0 |
Complement/biosynthesis | 2 | 28.0 |
Alopecia Areata/*immunology | 3 | 50.0 |
Spain | 2 | 0.0 |
Monocytes/*immunology | 2 | 0.0 |
Complement 9 | 3 | 42.0 |
Cornea/*immunology | 3 | 25.0 |
Agammaglobulinemia/immunology | 2 | 15.0 |
Arthritis, Rheumatoid/immunology | 2 | 2.0 |
Lymphocytes/*immunology | 2 | 0.0 |
*Complement | 3 | 4.0 |
Trout | 2 | 14.0 |
Monocytes/*metabolism | 2 | 0.0 |
Complement 1/deficiency | 2 | 40.0 |
Ceruloplasmin/analysis | 2 | 6.0 |
Leukocytes/*immunology | 3 | 2.0 |
Complement 6/analysis | 4 | 30.0 |
Complement 7/analysis | 2 | 18.0 |
Transplantation, Homologous | 2 | 0.0 |
Synovial Fluid/immunology | 2 | 5.0 |
Culture Media | 2 | 0.0 |
Complement Factor B | 2 | 16.0 |
*Chemotaxis | 3 | 9.0 |
Immune Adherence Reaction | 2 | 4.0 |
Enzyme Activation | 2 | 0.0 |
Immunoelectrophoresis, Two-Dimensional | 3 | 2.0 |
African Continental Ancestry Group | 2 | 0.0 |
Antibodies, Bacterial/analysis | 2 | 5.0 |
*Cryoglobulins | 2 | 40.0 |
Magnesium | 2 | 8.0 |
Zymosan/*pharmacology | 2 | 25.0 |
Properdin | 2 | 33.0 |
Variation (Genetics) | 3 | 0.0 |
*Antigen-Antibody Complex | 2 | 3.0 |
Immunoglobulin G | 3 | 2.0 |
*Complement Fixation Tests | 2 | 28.0 |
*Complement/analysis | 2 | 25.0 |
Immunologic Deficiency Syndromes/*genetics/immunology | 2 | 13.0 |
Chemotaxis | 2 | 1.0 |
Histamine Release | 2 | 3.0 |
Macaca | 2 | 2.0 |
Goats/immunology | 2 | 9.0 |
Immunoglobulin M | 2 | 6.0 |
Rabbits/immunology | 2 | 2.0 |
*Genetics, Population | 2 | 0.0 |
*Immunoglobulin Allotypes | 2 | 25.0 |
